edison tv
Investment Companies
“Edison is the go-to for a new investor to get full understanding of the investment case and business. Edison’s distribution reaches investors that we want to connect with directly.”
Associated equity: BioPorto Diagnostics
Edison Investment Research is terminating coverage on BioPorto Diagnostics. Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.
Previously published reports can still be accessed via our website.
BioPorto Diagnostics — 2 videos in collection
BioPorto is a Denmark-based in vitro diagnostics company that uses antibody and assay expertise to transform novel research tools into clinically actionable biomarkers. The company’s portfolio includes The NGAL Test for the prediction of acute kidney injury and an extensive antibody library.
In this video, Peter Eriksen, BioPorto’s chief executive officer, highlights the company’s year-end earnings results and discusses the status of its resubmission timeline to the FDA for pediatric The NGAL Test. He also provides an update on the corporate outlook for 2021 and reviews a new vision for the product portfolio with a focus on expanding BioPorto’s proprietary gRAD technology.
Get access to the very latest content matched to your personal investment style.